News

Futura Medical is expecting that the regulatory dossier for CSD500, will allow the CE mark approval process to be completed later in 2010. Futura Medical said the submission

Abbott’s test would be able to detect NGAL about two days earlier than the widely used method for the detection of AKI, a serum creatinine blood test. According

As per the terms of the agreement, Bristol-Myers Squibb has agreed to pay NeurOp an upfront fee of $1.5m and to fund a two-year research collaboration. In addition,

China Baicaotang posted a net income of $4.03m, or $0.13 per diluted share, compared to $3.07m, or $0.10 per diluted share, for the same period in 2008. Operating

Eribulin, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Eisai said that the submissions are based primarily on data from a

Aildenafil is close in structure to Sildenafil and is expected to possess a similar pharmacological and adverse event profile. Sildenafil is the active pharmaceutical ingredient in an FDA-approved

Alnylam said that in May 2008, the Japanese Patent Office had granted a related set of claims in the Tuschl II patent series (JP 4 095 895). The

Titan Pharma said that the Phase 3 study will be conducted at approximately 23 sites in the US and randomise approximately 250 patients into three arms: Probuphine (100

Antisense therapies target the proteins involved in disease processes through the RNA that is involved in building these proteins. The Isis discovery platform develops specific therapies that bind